COLL Q3 2024 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$159M+16.5% YoY

Gross Profit

$97M60.8% margin

Operating Income

$35M21.9% margin

Net Income

$9M5.9% margin

EPS (Diluted)

$0.27

QoQ Revenue Growth

+9.7%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$1.4B

Stockholders' Equity

$234M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$159M	$137M	+16.5%
Gross Profit	$97M	$80M	+20.5%
Operating Income	$35M	$45M	-22.6%
Net Income	$9M	$21M	-54.8%

Revenue Segments

Belbuca

$53M35%

Xtampza ER

$49M33%

Nucynta IR

$25M17%

Nucynta ER

$20M13%

Symproic

$4M2%